Bone metastases in patients with metastatic renal cell carcinoma (mRCC) do not independently affect oncologic outcomes or survival, according to data presented at SUO 2020, a virtual annual meeting sponsored by the Society of Urologic Oncology.
Juan Javier-DesLoges, MD, an SUO fellow at UC San Diego Health in La Jolla, California, and colleagues studied 447 patients with mRCC, of whom 124 had bone metastases and 323 did not. The investigators stratified 361 patients according to Memorial Sloan Kettering Cancer Center/Motzer risk categories: low-risk, 30 patients; intermediate-risk, 208 patients; and high-risk, 123 patients. Median follow-up duration was 14.3 months. Progression-free survival (PFS) and overall survival (OS) were the primary and secondary outcomes, respectively.
Multivariate analyses revealed no significant effect of bone metastases on PFS, but showed that higher Motzer risk categories independently predicted increased PFS and mortality risk.
Kaplan-Meier analyses found no significant difference between the patients with bone metastases and those without bone metastases with regard to median PFS (6.1 vs 6.4 months, respectively) and median OS (25.5 vs 26.5 months, respectively). Stratification by risk categories did not demonstrate any differences in PFS and OS between patients with and without bone metastases, the investigators reported.
“The prognostic significance of bone metastases may be less than previously hypothesized, and further study is needed in this select group of patients,” the authors concluded.
Javier-DesLoges J, Bradshaw A, Mir MC, et al. Does presence of bone metastases portend worsened prognosis in renal cell carcinoma? Analysis of the REMARCC (Registry of MetAstatic RCC) database. Presented at: SUO 2020, December 3-5, 2020. Poster 84.
This article originally appeared on Renal and Urology News